Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.
There was an improvement in progression-free survival despite crossover.
The phase 3 CanStem111P study was terminated early due to futility.
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
Most vaccinated patients reported having mild side effects or none at all.
Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.
The researchers also projected an increase in cancer deaths.